PharmacoEconomics

Primary Care Purchasing: Are Integrated Primary Care Provider/Purchasers the Way Forward?
pp. 209-216(8)
Author: Peckham S.

Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens
pp. 217-228(12)
Author: Urquhart J.

The Economics of Multiple Sclerosis: Distribution of Costs and Relationship to Disease Severity
pp. 229-240(12)
Authors: Grudzinski A.N.; Hakim Z.; Cox E.R.; Bootman J.L.

Patient Self-Reports in Pharmacoeconomic Studies: Their Use and Impact on Study Validity
pp. 241-256(16)
Authors: Evans C.; Crawford B.

Under-Utilisation of -Blockers After Acute Myocardial Infarction: Pharmacoeconomic Implications
pp. 257-268(12)
Authors: Bradford W.D.; Chen J.; Krumholz H.M.

New Drugs for Osteoporosis: Comparison of the Costs and Required Returns With Those of Other Drugs Intended for Long-Term Use
pp. 269-278(10)
Author: Edwards M.

Simvastatin After Orthotopic Heart Transplantation: Costs and Consequences
pp. 279-289(11)
Authors: Krobot K.J.; Wenke K.; Reichart B.

Pharmaceutical Price Regulation: A Study on the Impact of the Rate-of-Return Regulation in the UK
pp. 291-303(13)
Author: Borrell J-R.

Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma
pp. 305-311(7)
Authors: Uyl-de Groot C.A.; Ossenkoppele G.J.; Buijt I.; Huijgens P.C.